CRGY Energy · Oil and gas · U.S. producer · M&A · Thesis updated July 2, 2026

Integration is working, but debt still bites

Crescent is now a larger three-basin oil and gas producer after the Vital Energy merger.
Q1 production beat expectations, helped by faster Permian cycle times and stronger base production.
Management says it has captured $120 million of Vital synergies and over $500 thousand of savings per well.
Crescent Royalties is becoming more visible, with 2026 EBITDA now expected near $200 million at current prices.
The stock looks tied to execution: free cash flow, debt reduction, and dilution from the 2031 convertible notes.

01 Running thesis

The deal machine is proving itself

Crescent's story has moved from closing the Vital Energy deal to proving it can run the bigger company well. Q1 helped. Production came in ahead of expectations, mainly from faster cycle times in the Permian and better base production. Management also said Vital integration is ahead of plan.

The bull case is clearer now. Crescent says it has captured $120 million of synergies, above its first target, and has cut well costs by over $500 thousand per well versus the prior operator. If those savings repeat, Crescent's acquisition-led model looks less risky. The separate Crescent Royalties business also matters because management now expects about $200 million of 2026 EBITDA at current commodity prices.

The bear case has not gone away. This is still an oil and gas company, so commodity prices can move cash flow fast. Crescent also issued $690 million of 2.750% convertible senior notes due 2031 to refinance debt. That may lower interest cost, but it can dilute shareholders if the notes convert.

The key test over the next year is simple: can Crescent turn better operations into lasting free cash flow while reducing debt. Management expects full-year production and capital spending to land in the upper half of guidance, but investors still need a formal update and proof that Permian cost savings are structural, not just a temporary service-cost benefit.

May 2026▲Q1 production beat expectations, and management said Vital integration is ahead of plan. Crescent also raised the outlook for Crescent Royalties to about $200 million of 2026 EBITDA at current prices.

May 2026→The Q1 10-Q showed active balance sheet work, including $690 million of 2031 convertible notes used in part to redeem 2028 notes. It also showed about $358 million of new mineral and royalty acquisitions, but levered free cash flow fell 21% year over year.

Feb 2026▲Management doubled the Vital synergy target and launched Crescent Royalties as a clearer business line. Debt reduction stayed the near-term capital allocation focus.

Feb 2026▲The 2025 10-K confirmed the Vital Energy merger closed and that non-core asset sale agreements totaled more than $900 million. The story shifted from closing the deal to integrating a bigger three-basin company.

Nov 2025▲Crescent said it had signed more than $800 million of non-core divestitures. Management expected the proceeds to reduce debt tied to the Vital acquisition.

Nov 2025→The all-equity Vital Energy merger became the center of the thesis. It added scale and a clear synergy target, but also raised execution risk.

Aug 2025▲Q2 showed record production of 263,000 barrels of oil equivalent per day and about $171 million of free cash flow. Management framed capital allocation as roughly 80% debt reduction and 20% shareholder returns.

Aug 2025▲The Q2 10-Q showed faster buybacks and a refinancing of part of the 2028 notes with 2034 notes. Crescent also added U.S. tariff and trade policy as a risk to monitor.

02 Business model

Buy fields, drill wells, hedge cash flow

Crescent makes most of its money by selling crude oil, natural gas, and natural gas liquids. For 2025, oil was 69% of production revenue, natural gas was 20%, and NGLs were 11%. It also earns a small amount, less than 5% of revenue, from midstream assets and related work.

The company aims to buy assets at attractive prices, improve how they are run, and return some cash to shareholders. Its asset mix includes low-decline production, which means wells that fall off more slowly, plus development inventory that needs new capital to drill.

Crescent uses hedges, which are contracts that lock in part of future oil and gas prices. Hedges can protect cash flow when prices fall, but they can also limit upside when prices rise. The model works best when acquired assets beat cost and production targets while commodity prices stay supportive.

The weak spot is the balance sheet. Crescent has been active in refinancing, including the $690 million convertible note deal in Q1 2026. Still, higher development spending and interest expense helped push levered free cash flow down 21% year over year in Q1 2026, even though Adjusted EBITDAX rose.

03 Product portfolio

Oil leads, royalties add leverage

Cash cow

Crude oil

Oil is Crescent's largest product line. It made up 69% of 2025 production revenue, so oil prices are the biggest driver of results.

Steady

Natural gas

Natural gas was 20% of 2025 production revenue. The mix has shifted more toward gas than in the prior year, which adds price exposure beyond oil.

Steady

Natural gas liquids

NGLs were 11% of 2025 production revenue. They are tied to gas processing and can move differently than crude oil.

Option

Crescent Royalties

Crescent Royalties holds minerals and royalty interests. Management expects about $200 million of 2026 EBITDA at current prices, making it a possible value-unlock story.

Steady

Midstream and other

Midstream assets and related activities are small, at less than 5% of revenue. They support the upstream business but do not drive the thesis.

04 Business segments

Working interest still dominates

Working interest assets97%modest

Minerals and royalties assets3%growing fast

The mix uses Q1 2026 production volumes disclosed for working interest assets and minerals and royalties assets. Working interest assets were 330 MBoe/d, while minerals and royalties were 11 MBoe/d, so the royalty business is much smaller by volume but higher margin.

05 Risk factors

What could break the story

Commodity price shock

High impact · High odds

Crescent sells oil, natural gas, and NGLs, so lower prices can cut revenue and free cash flow quickly. Hedges protect part of production, but not all of it. A long price downturn would also make debt reduction harder.

We watchWatch realized oil, natural gas, and NGL prices, plus hedge gains or losses in quarterly filings.

Permian savings fade

High impact · Medium odds

Management says it has saved over $500 thousand per well versus the prior operator. The open question is how much of that is permanent process improvement versus lower service prices. If savings fade, the Vital deal looks less powerful.

We watchWatch well cost updates, cycle-time data, and whether management raises or cuts the synergy target.

Convertible note dilution

Medium impact · Medium odds

Crescent issued $690 million of 2.750% convertible senior notes due 2031. The refinancing helps address higher-coupon debt, but conversion can dilute shareholders. It can also affect reported financial results.

We watchWatch the share count, diluted EPS calculations, and any disclosure about the conversion value of the 2031 notes.

Free cash flow squeezed by capex

High impact · Medium odds

Q1 2026 levered free cash flow fell 21% year over year, mainly because development spending rose by $177.2 million and interest expense increased. Crescent can be operationally better and still disappoint if growth spending absorbs the cash. That is the main tension between drilling, debt paydown, and shareholder returns.

We watchWatch levered free cash flow, development spending, and the split between debt reduction, dividends, and buybacks.

Royalty value does not surface

Medium impact · Medium odds

Crescent is giving Crescent Royalties a clearer profile and a dedicated credit facility. That could help investors value it separately. But if leverage does not move toward the 1.5x target or if no strategic action follows, the market may not give Crescent credit for it.

We watchWatch CRF EBITDA, CRF leverage, royalty acquisitions, and any sale, spin, or financing action tied to the royalty portfolio.

06 Quick answers

In one breath

What does Crescent Energy do?

Crescent Energy buys and develops U.S. oil and gas assets. Its main products are crude oil, natural gas, and NGLs, with operations focused in the Eagle Ford, Permian, and Uinta.

Why does the Vital Energy deal matter?

Vital gave Crescent a scaled entry into the Permian. Management says the integration is ahead of plan, with $120 million of synergies captured and over $500 thousand of well cost savings per well.

What is Crescent Royalties?

Crescent Royalties is the company's minerals and royalties business. It produced 11 MBoe/d in Q1 2026 and is expected to generate about $200 million of EBITDA in 2026 at current commodity prices.

What is the biggest risk for CRGY stock?

The biggest risk is a mix of commodity prices, debt, and execution. Crescent needs to keep improving the acquired assets while turning those gains into free cash flow and lower leverage.